Fabry DiseasePhase 1/2NCT04046224

Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)

A Phase 1/2 study testing ST-920 in people with Fabry Disease, run by Sangamo Therapeutics at 18 sites in 7 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Fabry Disease
What is being tested?: ST-920
Type of treatment: Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 36 participants
Where: 18 sitesin 7 countries
Study dates: 23 Jul 2019to 10 Apr 2025
Phase: Phase 1/2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

≥ 18 years of age
Documented diagnosis of Fabry disease
One or more of the following symptoms: i) cornea verticillata, ii) acroparesthesia, iii) anhidrosis, iv) angiokeratoma
Subject must be fully vaccinated (as per the Centers for Disease Control and Prevention (CDC) definition in the US and as per local guidelines in other countries) for Coronavirus Disease (COVID-19) at least one month prior to dosing
Additional Inclusion Criteria:
Renal Cohort:

Show all 10Show fewer

Screening estimated glomerular filtration rate (eGFR) value between 40-90 mL/min/1.73 m²
Linear negative eGFR slope (estimated from at least 3 serum creatinine values within 18 months, including the value obtained during screening visit) of ≥ 2 mL/min/1.73m²/year
Cardiac Cohort:
Left ventricular hypertrophy (LVH) in 2D echocardiography or cardiac magnetic resonance imaging (CMR) defined as an end diastolic septum and posterior wall thickness ≥12 mm with no other explanation for LVH, OR presentation with cardiac changes indicative of disease progression such as decreased global longitudinal strain on 2D strain echocardiography or low native T1 mapping on CMR

Who cannot join

Neutralizing antibodies to AAV6
eGFR < 40 ml/min/1.73m2
New York Heart Association Class III or higher
Active infection with hepatitis A, B or C, human immunodeficiency virus (HIV) or tuberculosis (TB)
History of liver disease such as clinically significant steatosis, fibrosis, non-alcoholic steatohepatitis (NASH) and cirrhosis, biliary disease within 6 months of informed consent; except for Gilbert's syndrome
Elevated circulating serum alpha fetoprotein (AFP)

Show all 26Show fewer

Recent or recurrent hypersensitivity response to enzyme replacement therapy (ERT) within within 6 months prior to consent
Current or history of systemic (IV or oral) immunomodulatory agents, or biologics or steroid use in the past 6 months prior to consent (topical treatment and inhaled allowed).
Contraindication to use of corticosteroids
History of malignancy except for non-melanoma skin cancer and localized prostate cancer treated with curative intent
Recent history of alcohol or substance abuse
Participation in investigational interventional drug or medical device study throughout the duration of this study and within previous 3 months prior to consent
Prior treatment with a gene therapy product
Known hypersensitivity to components of ST-920 formulation
Any other reason that, in the opinion of the Site Investigator or Medical Monitor, would render the subject unsuitable for participation in the study including but not limited to risk of COVID-19 infection
Additional exclusion criteria for:
Renal cohort:
History of renal dialysis or transplantation
History of acute kidney insufficiency in the 6 months prior to screening
Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated within 4 weeks prior to screening or changed ACE inhibitor or ARB dose in the 4 weeks prior to screening
Urine protein to creatinine ratio (UPCR) > 0.5 g/g who are not being treated with an ACE inhibitor or ARB
Cardiac cohort:
Significant cardiac fibrosis defined by late gadolinium enhancement on CMR
Any contraindications to CMR as per local hospital/institution guidelines
Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated within 4 weeks prior to screening or changed ACE inhibitor or ARB dose in the 4 weeks prior to screening
New York heart association (NYHA) Class IV

Trial locations and contacts

18 sites in 7 countries.

Country

City, postcode or hospital

18 sites in 7 countries

United States9 sites

Emory University School of Medicine
Atlanta, Georgia, 30322
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)
Fairfax, Virginia, 22030
University of Iowa Hospital and Clinics
Iowa City, Iowa, 52242
University of California, Irvine
Irvine, California, 92697
University of Minnesota Medical Center
Minneapolis, Minnesota, 55455
Mt. Sinai School of Medicine
New York, New York, 10029
University of South Florida
Tampa, Florida, 33620

Other trials in United States

United Kingdom3 sites

Queen Elizabeth Hospital
Birmingham, B15 2TH
Addenbrooke's Hospital
Cambridge, CB2 0QQ
Royal Free Hospital
London

Other trials in United Kingdom

Germany2 sites

University Medical Center Hamburg-Eppendorf
Hamburg
University Hospital of Würzburg
Würzburg

Other trials in Germany

Australia1 site

The Royal Melbourne Hospital
Parkville, Victoria, 3050

Other trials in Australia

Canada1 site

M.A.G.I.C. Clinic Ltd.
Calgary, Alberta, T2E 7Z4

Other trials in Canada

Italy1 site

Azienda Ospedaliero-Universitaria Careggi
Florence, Tuscany, 50134

Other trials in Italy

Taiwan1 site

National Taiwan University Hospital
Taipei

Other trials in Taiwan

About this study

Official title: A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)

This is the first in human treatment with ST-920, an adeno-associated virus (AAV2/6) vector encoding the complementary deoxyribonucleic acid (cDNA) for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of 52 weeks.

Conditions: Fabry Disease
Being tested: ST-920
Keywords: Sangamo, Rare, Lysosomal Storage Disease, Gene Therapy
Medical subject headings: Fabry Disease, Lysosomal Storage Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

ST-920Biological
Single dose of investigational product ST-920

Study groups in NCT04046224
Study group	Role	What they receive
Sequential dose escalation	Experimental	ST-920 is administered as a single infusion: 1. Cohort 1: 0.5e13 vg/kg 2. Cohort 2: 1.0e13 vg/kg 3. Cohort 3: 3.0e13 vg/kg 4. Cohort 4: 5.0e13 vg/kg Receives: Biological: ST-920
Expansion Cohorts	Experimental	1. Anti Alpha-Gal A Antibody Positive Cohort 2. Anti Alpha-Gal A Antibody Negative Cohort 3. Female Cohort 4. Renal Cohort 5. Cardiac Cohort Receives: Biological: ST-920

What is being measured

The primary outcome is the main question the study is designed to answer.

Incidence of Treatment-emergent Adverse Events (TEAEs) - All
All incidences of Treatment-Emergent Adverse Events (TEAEs) in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Measured: Up to 12 months after the ST-920 infusion
Incidence of Treatment-emergent Adverse Events (TEAEs) - Related to ST-920
Incidences of Treatment-Emergent Adverse Events (TEAEs) directly related to ST-920 in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Measured: Up to 12 months post ST-920 infusion
Incidence of Treatment-emergent Adverse Events (TEAEs) - Serious
All incidences of serious Treatment-Emergent Adverse Events (TEAEs) in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Measured: Up to 12 month post ST-920 infusion
Incidence of Treatment-emergent Adverse Events (TEAEs) - Any TEAEs Leading to Study Discontinuation or Withdrawal
All incidences of Treatment-Emergent Adverse Events (TEAEs) that lead to study discontinuation or withdrawal in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Measured: Up to 12 month post ST-920 infusion

Secondary outcomes (1)

To Assess Alpha Gal-A Activity in Plasma Over Time
Change in alpha Gal-A activity in plasma from baseline at specific time points over the 1-year study period. Two collections occurred during the baseline period and the latter of the two collections was used for the baseline value. The specific time points are Week 24 and Week 52/End of Study (EOS). Plasma α-Gal A activity was measured using a validated fluorometric enzyme activity assay.
Measured: up to 12 months post ST-920 infusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

23 Jul 201910 Apr 2025

First posted6 Aug 2019
Study start23 Jul 2019
Primary completion10 Apr 2025
Study completion10 Apr 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Fabry DiseaseStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1/2
Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Sequential
Masking: None (open label)
Enrolment: 36 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04046224
Sponsor's protocol ID: ST-920-201
Status last verified: Oct 2026
First submitted: 1 Aug 2019
Last updated: 27 Oct 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingPhase 3
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Fabry Disease
RecruitingObservational study
A Study of Patients With Fabry Disease (US Specific)
Fabry Disease
RecruitingObservational study
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Fabry Disease
Active, not recruiting
Evaluation of the Effect of a Low-FODMAP Diet on Gastrointestinal Symptoms and Inflammatory Markers in Fabry Patients
Fabry Disease
RecruitingPhase 3
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Fabry Disease

All Fabry Disease trials

Study at a glance

From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
ClinicalTrials.gov ID: NCT04046224
Acronym / sponsor ID: ST-920-201
Conditions: Fabry Disease
Keywords: Sangamo, Rare, Lysosomal Storage Disease, Gene Therapy
Phase: Phase 1/2
Study type: Interventional
Recruitment status: Completed
Enrolment: 36 participants (actual)
Lead sponsor: Sangamo TherapeuticsIndustry (pharma, biotech, devices)
Study start: 23 Jul 2019 (actual)
Primary completion: 10 Apr 2025 (actual)
Study completion: 10 Apr 2025 (actual)
First posted: 6 Aug 2019 (actual)
Results: Posted 14 Apr 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Sequential
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Sequential dose escalation	Experimental	Biological: ST-920ST-920 is administered as a single infusion: 1. Cohort 1: 0.5e13 vg/kg 2. Cohort 2: 1.0e13 vg/kg 3. Cohort 3: 3.0e13 vg/kg 4. Cohort 4: 5.0e13 vg/kg
Expansion Cohorts	Experimental	Biological: ST-9201. Anti Alpha-Gal A Antibody Positive Cohort 2. Anti Alpha-Gal A Antibody Negative Cohort 3. Female Cohort 4. Renal Cohort 5. Cardiac Cohort

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (10 listed)

≥ 18 years of age
Documented diagnosis of Fabry disease
One or more of the following symptoms: i) cornea verticillata, ii) acroparesthesia, iii) anhidrosis, iv) angiokeratoma
Subject must be fully vaccinated (as per the Centers for Disease Control and Prevention (CDC) definition in the US and as per local guidelines in other countries) for Coronavirus Disease (COVID-19) at least one month prior to dosing
Screening estimated glomerular filtration rate (eGFR) value between 40-90 mL/min/1.73 m²

Key exclusion criteria (26 listed)

Neutralizing antibodies to AAV6
eGFR < 40 ml/min/1.73m2
New York Heart Association Class III or higher
Active infection with hepatitis A, B or C, human immunodeficiency virus (HIV) or tuberculosis (TB)
History of liver disease such as clinically significant steatosis, fibrosis, non-alcoholic steatohepatitis (NASH) and cirrhosis, biliary disease within 6 months of informed consent; except for Gilbert's syndrome

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
ST-920Single dose of investigational product ST-920	Biological	Expansion Cohorts, Sequential dose escalation

Primary outcome

Incidence of Treatment-emergent Adverse Events (TEAEs) - All
Time frame: Up to 12 months after the ST-920 infusion
All incidences of Treatment-Emergent Adverse Events (TEAEs) in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Incidence of Treatment-emergent Adverse Events (TEAEs) - Related to ST-920
Time frame: Up to 12 months post ST-920 infusion
Incidences of Treatment-Emergent Adverse Events (TEAEs) directly related to ST-920 in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Incidence of Treatment-emergent Adverse Events (TEAEs) - Serious
Time frame: Up to 12 month post ST-920 infusion
All incidences of serious Treatment-Emergent Adverse Events (TEAEs) in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Incidence of Treatment-emergent Adverse Events (TEAEs) - Any TEAEs Leading to Study Discontinuation or Withdrawal
Time frame: Up to 12 month post ST-920 infusion
All incidences of Treatment-Emergent Adverse Events (TEAEs) that lead to study discontinuation or withdrawal in subjects who receive ST-920 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)

1 secondary outcome

To Assess Alpha Gal-A Activity in Plasma Over Time
Time frame: up to 12 months post ST-920 infusion

Results and safety

Results posted to the registry on 14 Apr 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Dose Level 1 (0.26E + 13 vg/kg)	2	2
Dose Level 2 (0.53E + 13 vg/kg)	2	2
Dose Level 3 (1.58E + 13 vg/kg)	3	3
Dose Level 4 (2.63E +13 vg/kg)	2	2
Expansion - Cardiac Group (2.63E+13 vg/kg)	5	4
Expansion - Female Group (2.63E+13 vg/kg)	5	5
Expansion - Renal Group (2.63E+13 vg/kg)	2	2
Expansion - Anti Alpha Gal-A Negative (2.63E+13 vg/kg)	7	7
Expansion - Anti Alpha Gal-A Positive (2.63E+13 vg/kg)	5	5

Primary outcome: Incidence of Treatment-emergent Adverse Events (TEAEs) - All

Time frame: Up to 12 months after the ST-920 infusion. Count of participants. Unit: Participants

Measure	Dose Level 1 (0.26E+13 vg/kg) n = 2	Dose Level 2 n = 2	Dose Level 3 n = 3	Dose Level 4 n = 2	Expansion - Cardiac Group (2.63E+13 vg/kg) n = 5	Expansion - Female Group (2.63E+13 vg/kg) n = 5	Expansion - Renal Group (2.63E+13 vg/kg) n = 2	Expansion - Anti Alpha Gal-A Negative (2.63E+13 vg/kg) n = 7	Expansion - Anti Alpha Gal-A Positive (2.63E+13 vg/kg) n = 5
Value	2	2	3	2	5	5	2	7	5

Population analysed: Safety population

Primary outcome: Incidence of Treatment-emergent Adverse Events (TEAEs) - Related to ST-920

Time frame: Up to 12 months post ST-920 infusion. Count of participants. Unit: Participants

Measure	Dose Level 1 (0.26E+13 vg/kg) n = 2	Dose Level 2 n = 2	Dose Level 3 n = 3	Dose Level 4 n = 2	Expansion - Cardiac Group (2.63E+13 vg/kg) n = 5	Expansion - Female Group (2.63E+13 vg/kg) n = 5	Expansion - Renal Group (2.63E+13 vg/kg) n = 2	Expansion - Anti Alpha Gal-A Negative (2.63E+13 vg/kg) n = 7	Expansion - Anti Alpha Gal-A Positive (2.63E+13 vg/kg) n = 5
Value	0	0	0	0	5	4	2	7	5

Population analysed: Safety population

Primary outcome: Incidence of Treatment-emergent Adverse Events (TEAEs) - Serious

Time frame: Up to 12 month post ST-920 infusion. Count of participants. Unit: Participants

Measure	Dose Level 1 (0.26E+13 vg/kg) n = 2	Dose Level 2 n = 2	Dose Level 3 n = 3	Dose Level 4 n = 2	Expansion - Cardiac Group (2.63E+13 vg/kg) n = 5	Expansion - Female Group (2.63E+13 vg/kg) n = 5	Expansion - Renal Group (2.63E+13 vg/kg) n = 2	Expansion - Anti Alpha Gal-A Negative (2.63E+13 vg/kg) n = 7	Expansion - Anti Alpha Gal-A Positive (2.63E+13 vg/kg) n = 5
Value	0	0	0	0	0	0	1	1	1

Population analysed: Safety population

Primary outcome: Incidence of Treatment-emergent Adverse Events (TEAEs) - Any TEAEs Leading to Study Discontinuation or Withdrawal

Time frame: Up to 12 month post ST-920 infusion. Count of participants. Unit: Participants

Measure	Dose Level 1 (0.26E+13 vg/kg) n = 2	Dose Level 2 n = 2	Dose Level 3 n = 3	Dose Level 4 n = 2	Expansion - Cardiac Group (2.63E+13 vg/kg) n = 5	Expansion - Female Group (2.63E+13 vg/kg) n = 5	Expansion - Renal Group (2.63E+13 vg/kg) n = 2	Expansion - Anti Alpha Gal-A Negative (2.63E+13 vg/kg) n = 7	Expansion - Anti Alpha Gal-A Positive (2.63E+13 vg/kg) n = 5
Value	0	0	0	0	0	0	0	0	0

Population analysed: Safety population

1 secondary outcome is reported in the full results.

Adverse events

Time frame: Adverse events were collected for a period of 1 year post dose.. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Dose Level 1 (0.26E +13 vg/kg)	0 of 2 (0%)	2 of 2 (100%)	0 of 2
Dose Level 2 (0.53E + 13 vg/kg)	0 of 2 (0%)	2 of 2 (100%)	0 of 2
Dose Level 3 (1.58E + 13 vg/kg)	1 of 3 (33.3%)	3 of 3 (100%)	0 of 3
Dose Level 4 (2.63E +13 vg/kg)	0 of 2 (0%)	2 of 2 (100%)	0 of 2
Expansion - Cardiac Group (2.63E+13 vg/kg)	0 of 5 (0%)	5 of 5 (100%)	0 of 5
Expansion - Female Group (2.63E+13 vg/kg)	0 of 5 (0%)	5 of 5 (100%)	0 of 5
Expansion - Renal Group (2.63E+13 vg/kg)	1 of 2 (50%)	2 of 2 (100%)	0 of 2
Expansion - Anti Alpha Gal-A Negative (2.63E+13 vg/kg)	1 of 7 (14.3%)	7 of 7 (100%)	0 of 7
Expansion - Anti Alpha Gal-A Positive (2.63E+13 vg/kg)	1 of 5 (20%)	5 of 5 (100%)	0 of 5

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Fabry Disease

RecruitingPhase 3
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Fabry Disease
RecruitingObservational study
A Study of Patients With Fabry Disease (US Specific)
Fabry Disease
RecruitingObservational study
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Fabry Disease
Active, not recruiting
Evaluation of the Effect of a Low-FODMAP Diet on Gastrointestinal Symptoms and Inflammatory Markers in Fabry Patients
Fabry Disease
RecruitingPhase 3
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Fabry Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Medical Monitor study director

Sangamo Therapeutics, Inc.

18 sites in 7 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing ST-920 in people with Fabry Disease, run by Sangamo Therapeutics at 18 sites in 7 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in United States, United Kingdom, Germany, Australia, Canada and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Treatment-emergent Adverse Events (TEAEs) - All (time frame: Up to 12 months after the ST-920 infusion). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04046224.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.